

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Schwarz, et al.
Serial No.: 09/439,616
Filed: November 12, 1999
For: *METHODS OF FACILITATING VASCULAR GROWTH*

August 13, 2001

BOX PATENT APPLICATION
Commissioner for Patents
Washington, DC 20231

STATEMENT IN LIEU OF FILING A
SEQUENCE LISTING UNDER 37 CFR § 1.821(e)


Sir:

A paper copy of the computer-readable form is of record in this case on pages 26-28 of the specification.

I hereby request that the sequence listing already on file in parent application Serial No. 09/439,616, be used in this case in lieu of filing a duplicate computer readable form herein. I hereby state that the copy of the sequence listing in this application is identical to the computer readable form filed in said previous application, and that no new matter is added.

If there are any further requirements necessary to comply with the Sequence Listing rules in this case, please contact Applicants' undersigned representative at your earliest convenience.

Respectfully submitted,


Kenneth D. Sibley
Attorney for Applicant
Registration No. 31,665



20792

PATENT TRADEMARK OFFICE

SEQUENCE LISTING

5 <110> Schwarz, Margaret A.
 Zhang, Fangrong
 Gebb, Sarah A.
 <120> Methods of Facilitating Vascular Growth
 10 <130> EMAP2 and Vascularization
 <140>
 <141>
 15 <150> 60/108,435
 <151> 1998-11-13
 <160> 12
 20 <170> PatentIn Ver. 2.0
 <210> 1
 <211> 20
 <212> DNA
 25 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: primer
 30 <400> 1
 gtcattggcca tggctgagta 20
 <210> 2
 <211> 20
 <212> DNA
 35 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: primer
 40 <400> 2
 ctctctcggca tcttgctgaa 20
 <210> 3
 <211> 19
 45 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: primer
 50 <400> 3
 ttgaagtgcac gaatgagat 19
 <210> 4
 55 <211> 19
 <212> DNA
 <213> Artificial Sequence
 <220>
 60 <223> Description of Artificial Sequence: primer

	<400> 4	
	atttagagct gtctggctt	19
5	<210> 5	
	<211> 21	
	<212> DNA	
	<213> Artificial Sequence	
10	<220>	
	<223> Description of Artificial Sequence: primer	
	<400> 5	
	catactgaga tggtccttga g	21
15	<210> 6	
	<211> 21	
	<212> DNA	
	<213> Artificial Sequence	
20	<220>	
	<223> Description of Artificial Sequence: primer	
	<400> 6	
25	tctggagcca tcttcatgat g	21
	<210> 7	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	
30	<220>	
	<223> Description of Artificial Sequence: primer	
	<400> 7	
35	gaacatgaga gtacgaccac tgtcaaa	27
	<210> 8	
	<211> 27	
	<212> DNA	
40	<213> Artificial Sequence	
	<220>	
	<223> Description of Artificial Sequence: primer	
45	<400> 8	
	ttagggcgag aaccttccag aaatctt	27
	<210> 9	
	<211> 21	
50	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Description of Artificial Sequence: primer	
55	<400> 9	
	gtatggaatc ctgtggcatc c	21
	<210> 10	
60	<211> 21	
	<212> DNA	

<213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: primer
 5 <400> 10
 tacgcagctc agtaacagtc c 21
 <210> 11
 10 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Description of Artificial Sequence: primer
 <400> 11
 cataactgaga tggtccttga g 21
 <210> 12
 20 <211> 21
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <223> Description of Artificial Sequence: primer
 <400> 12
 tctggagcca tcttcatgat g 21